An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of KW-2449 in Acute Leukemias (AML), Myelodysplastic Syndromes (MDS), and Chronic Myelogenous Leukemia (CML)
Sponsor: Kyowa Kirin, Inc.
Terminated
Terminated due to suboptimal dosing schedule
Other terminated trials from Kyowa Kirin, Inc.
- Apathy · Dec 2023
- Diabetic Kidney Disease · Phase PHASE3 · Jul 2023
- Follicular Lymphoma (FL) · Phase PHASE3 · Mar 2023
- Urothelial Carcinoma · Phase PHASE1 · Nov 2022
- Healthy Volunteers · Phase PHASE1 · Aug 2022
More terminations from Kyowa Kirin, Inc.
Other Acute Lymphoblastic Leukemia trials with similar outcome
This PHASE1 trial investigates Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia and is currently terminated or withdrawn. Kyowa Kirin, Inc. leads this study, which shows 8 recorded versions since 2006 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Terminated PHASE1
-
Oct 2021 — Jun 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE1
First recorded
Jun 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kyowa Kirin, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .